Cadila Healthcare, SJVN and NHPC to see some action today

27 Sep 2021 Evaluate

Cadila Healthcare has entered into an agreement with Shilpa Medicare for the production of its COVID-19 vaccine, ZyCoV-D. The company has entered into a definitive agreement with Shilpa Medicare, via its wholly-owned subsidiary, Shilpa Biologicals for production-supply of the ZyCoV-D vaccine drug substance from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka. The targeted production of the ZyCoV-D vaccine from this facility will be mutually agreed upon by both parties.

SJVN has bagged the full quoted capacity of 1000 MW at a Viability Gap Funding (VGF) support of Rs 44.72 lakh per MW by Government of India, through Request for Proposal (RFP) floated by Indian Renewable Energy Development Agency (IREDA). The tentative cost of Construction and Development of this Project is Rs 5500 crore. The project is expected to generate 2365 MU in the First year and the project cumulative energy generation over a period of 25 years would be about 55062 MU.

NHPC’s board has approved the proposal regarding formation of a Wholly Owned Subsidiary which will act as an investment vehicle and company for commissioned hydropower projects for facilitating the monetization of investment made, subject to approval of Government of India. The Board has also accorded its investment approval to contribute initial equity of Rs 5 crore by NHPC in the proposed Subsidiary Company. The Board of Directors of the company in its meeting held on September 24, 2021 has considered and approved the same.

Mindtree is expanding footprint in Europe and Asia-Pacific. The company has made several key executive appointments to further accelerate growth in the two markets. The company making sustained investments in Europe and Asia-Pacific as part of 4X4X4 strategy aimed at strengthening leadership capabilities and strategic partnerships in these markets to drive superior growth.

NBCC has secured the work order of 'Construction of 2000 Social Housing' at Hulhumale, Maldives on EPC basis. The total cost of the project is $130 million (Rs 968.50 crore).

Dalmia Bharat’s subsidiary -- Dalmia Cement has commenced commercial production of Line 2, having a capacity of 2.25 Million Tonnes at its Kapilas Cement Manufacturing Works (KCMW) Unit near Cuttack, Odisha. With this addition, the company's overall capacity at the plant has now gone up to 3.95 million tons per annum. This development is in line with the company's commitment towards fostering sustainable growth while also creating job opportunities in the region.

Ramkrishna Forgings has won an yet another export order worth Rs 30.00 crore ($4 million per annum) from the same North American Customer in Oil & Gas Segment. This order further strengthens penetration into this sector and is in line with the strategy to diversify its portfolio across sectors and geographies.

Zydus Lifesciences Share Price

953.50 20.10 (2.15%)
25-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1520.55
Dr. Reddys Lab 6217.15
Cipla 1405.40
Zydus Lifesciences 953.50
Lupin 1589.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.